Zelboraf Being Considered for FDA Approval

Zelboraf Being Considered for FDA Approval

FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation.